



Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020

January 6, 2020

SAN DIEGO, Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) on Monday, Jan. 13, 2020, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.



The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, uterine fibroids* and polycystic ovary syndrome*.

Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on [LinkedIn](https://www.linkedin.com/company/neurocrine). (**in collaboration with AbbVie*)

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-38th-annual-jp-morgan-healthcare-conference--live-audio-webcast-will-be-on-january-13-2020-300981951.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Navjot Rai (Media), 858-617-7623, media@neurocrine.com, or Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com